| Similar Articles |
|---|
 |
Chemistry World
April 17, 2008
Nuala Mora |
World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer.   |
The Motley Fool
May 28, 2010
Brian Orelli |
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. |
The Motley Fool
April 27, 2011
Brian Orelli |
Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug. |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
Chemistry World
September 2, 2014
Phillip Broadwith |
Exelexis slashes workforce by 70% The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer. |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
Pharmaceutical Executive
April 1, 2007 |
Deals: No IPO for Organon Akzo Nobel's plans to spin off its Organon Biosciences unit... Oxford BioMedica will acquire the privately held Oxxon Therapeutics... Jazz Pharmaceuticals has filed a registration statement with the SEC for... etc. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
Chemistry World
February 17, 2011
Sarah Houlton |
Sanofi to buy Genzyme in $20 billion deal Sanofi-Aventis has won its long-running battle for Genzyme, and is to acquire the US-based biotech for $74 ( 46) per share - about $20 billion in total - plus extra payments of up to $14 per share. |
The Motley Fool
September 14, 2009
Brian Orelli |
More Tests for Drug for Cancer Patients The Vanilla trial might not have come up positive, but at least sanofi-aventis and Regeneron Pharmaceuticals will keep trying to show that aflibercept is capable of helping cancer patients live longer. |
Managed Care
March 2007
Martin Sipkoff |
Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails. |
The Motley Fool
April 12, 2005
Brian Gorman |
Genentech's Cancer Quest The company's achievements in lung cancer further strengthen its reputation as a cancer fighter. Would-be investors are best served by waiting patiently. |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Finding a Cure for Cancer: The Option Market's Favorite Ideas What cancer stocks are investors taking seriously?: Allos Therapeutics... China Medical Technologies... Delcath Systems... Myriad Genetics... ZIOPHARM... |
Chemistry World
November 22, 2013
Emily James |
100 million for cancer research centers Cancer Research UK has invested 100 million pounds in 15 innovative research centers, acquiring high level expertise to solve the latest challenges in cancer. |
Pharmaceutical Executive
July 3, 2007
Sarah Houlton |
Global Report: Five-Year Survivor: European Edition The UK government's attitude seems to be that oncology treatments are hugely expensive -- and that too much of the National Health Service budget is vanishing into the pockets of drug companies. Will cancer networks fill the gap? |
BusinessWeek
April 30, 2007
Catherine Arnst |
Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced. |
Fast Company
July 1, 2007 |
Going on the Gold Standard What it takes for your company to join the cancer fight. |
Bio-IT World
May 2006 |
News Blast Aids Action... Oxford Universal... Myriad Options... |
The Motley Fool
August 31, 2005
Stephen D. Simpson |
Sanofi-Aventis: A Mix of News The company gave investors a lot of information for the second quarter, with not all of it positive. |
The Motley Fool
May 5, 2009
Robert Steyer |
Sanofi-Aventis' To-Do List The French drugmaker seeks acquisitions to reinforce and expand its business geographically and scientifically. |
BusinessWeek
May 23, 2005
Catherine Arnst |
If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer. |
Managed Care
March 2007
Lola Butcher |
Plans Put Greater Emphasis On Cancer Management Increasingly, health plans are rolling out services designed to help cancer patients and, before that, plan members at a high risk of cancer, to improve their health care and, in doing so, limit costs. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
American Family Physician
May 15, 2005 |
Early Prostate Cancer: What You Should Know A patient hand-out on the disease, who is at risk, diagnosis and treatment options. |
Science News
May 19, 2007 |
Science Safari: Cancer Risk -- Understanding the Puzzle This new Web site from the National Cancer Institute cuts through the hype to help you understand the plain and simple truth about cancer risk. |
American Family Physician
February 15, 2005 |
Health Care After Cancer Treatment An informative patient hand-out on follow-up cancer care. |
AskMen.com
Jacob Franek |
New Cancer Therapies As cancer research explodes, the availability of new and innovative interventions is expanding almost daily. |
AskMen.com
Dustin Driver |
8 Cancer Myths The following myths about cancer have been debunked by doctors and scientists the world over. So do yourself and your community a favor: read the facts and spread the word. |
The Motley Fool
May 13, 2005
Stephen D. Simpson |
Waiting for Sanofi's Next Act Sanofi-Aventis' first-quarter numbers were good. Will they soon be better? Though the stock is not the greatest idea for highly income-oriented investors, the growth-at-a-reasonable-price crowd might want to investigate further. |
Pharmaceutical Executive
February 1, 2013
William Looney |
In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer. |
American Journal of Nursing
March 2006
Pamela J. Haylock |
The Shifting Paradigm of Cancer Care: The Many Needs of Cancer Survivors Are Starting to Attract Attention The complexities of survivorship, and the growing population of survivors who share these challenges has led to an increase awareness of a need for survivorship research on the sequelae of cancer and cancer treatment. |
InsideFlyer
January 2009 |
United, Making Life Bearable United Airlines is once again teaming up with the American Cancer Society to bring a little happiness to children with cancer. |
The Motley Fool
October 27, 2006
Jack Uldrich |
Nanotech and the War on Cancer New imaging advances in nanotechnology will help speed cancers' end. What does it mean for investors? |
BusinessWeek
June 21, 2004
Catherine Arnst |
Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs. |
American Family Physician
February 15, 2005
Sunga et al. |
Care of Cancer Survivors Cancer survivors are at increased risk for recurrence of their original malignancy. Surveillance following curative cancer treatment generally includes interval history and physical examinations every six months for five years. |
Information Today
August 6, 2013 |
Oxford University Press Releases New and Updated Law Products The new products are Oxford Competition Law and Oxford Scholarly Authorities on International Law, and the updated products include Oxford Reports on International Law, the Max Planck Encyclopedia of Public International Law, and Investment Claims. |
